Interpretation of Controversial Teratogenic Findings of Drugs Such As Phenobarbital by Czeizel, Andrew E. et al.
International Scholarly Research Network
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 719675, 8 pages
doi:10.5402/2011/719675
Research Article
Interpretation of Controversial Teratogenic Findings of
Drugs Such As Phenobarbital
Andrew E. Czeizel,1 IstvanDud´ as,1 and Ferenc B´ anhidy2
1Foundation for the Community Control of Hereditary Diseases, Budapest 1026, Hungary
2Second Department of Obstetrics and Gynecology, School of Medicine, Semmelweis University, Budapest 1085, Hungary
Correspondence should be addressed to Andrew E. Czeizel, czeizel@interware.hu
Received 16 April 2011; Accepted 21 June 2011
Academic Editor: H. C. Wallenburg
Copyright © 2011 Andrew E. Czeizel et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objective. To check the debated association between phenobarbital treatment during pregnancy and risk for congenital
abnormalities (CAs) in their children. Study Design. It is a comparison of phenobarbital treatment in the mothers of cases with CA
and matched controls without CAs in the Hungarian Case-Control Surveillance System of Congenital Abnormalities. Results.O f
22,843 cases with CA, 149 (0.65%) had mothers with phenobarbital treatment, while of 38,151 control newborn infants without
CA, 209 (0.55%) were born to mothers with phenobarbital treatment (100–400mg daily) (OR with 95% CI:1.3, 1.1–1.7). Of 16
CAgroups,onlyhypospadiashadahigherriskafterphenobarbitaltreatmentinthecriticalperiodofthisCA(ORwith95%CI:2.4,
1.1–5.4). However, if only medically recorded phenobarbital treatments were evaluated and multiple testing bias was considered,
this association would disappear. Conclusions. This study stresses the importance of the exclusion of recall bias and multiple testing
bias.
1.Introduction
Phenobarbital has been used widely in clinical practice as a
sedative and anticonvulsant since 1912 [1] among pregnant
women as well. Phenobarbital crosses the placenta to the
fetus; however, this transfer is inﬂuenced by the duration
of treatment, pregnancy age, and arterial blood pH [2].
Previous studies showed controversial results regarding the
teratogenic eﬀect of phenobarbital [3–5], but the fetal risk
of phenobarbital was classiﬁed by the FDA in the pregnancy
category D (“There is positive evidence of human fetal
risk, but the beneﬁts from use in pregnant women may
be acceptable despite the risk ...”) [6]. Previously, we
evaluated the possible teratogenic eﬀect of phenobarbital
in the oﬀspring of pregnant women in the dataset of the
Hungarian Case-Control Surveillance System of Congenital
Abnormalities [7], and an association of oral phenobarbital
treatment with a higher risk of structural birth defects,
that is, congenital abnormalities (CAs) was not found (OR
with 95% CI: 1.1, 0.7–1.7). On the other hand, we used
the disaster epidemiological model for the evaluation of
phenobarbital teratogenicity in the children of 88 pregnant
women who attempted suicide with extremely large doses of
phenobarbital [8].
However, CAs cannot be regarded as a single homoge-
neous disorder group because teratogenic factors such as
drugs do not uniformly increase the rates of all CAs but
rather tend to increase the occurrence of one or a limited
number of speciﬁc CAs [9]. Thus, the objective of this study
was to evaluate again the possible association between oral
phenobarbital treatment in pregnant women and 16 CA-
groups separately in their oﬀspring in the population-based
large dataset of the Hungarian Case-Control Surveillance
System of congenital abnormalities (HCCSCA) [10]t o
understand better the controversial ﬁndings of previous
studies.
2.MaterialandMethods
The HCCSCA is based on the comparison between the rate
of exposures (i.e., phenobarbital in the study) in the mothers
of cases and controls during the study pregnancy.2 ISRN Obstetrics and Gynecology
The ﬁrst step was the selection of cases with diﬀerent
CA from the data set of the Hungarian Congenital Abnor-
mality Registry (HCAR), 1980–1996 [11] for the HCCSCA.
Reporting of CAs is mandatory for physicians from the birth
until the end of ﬁrst postnatal year to the HCAR. Most cases
with CA are reported by obstetricians and paediatricians.
In Hungary, practically all deliveries take place in inpatient
obstetric clinics, and the birth attendants are obstetricians.
In addition, all infants aﬀected with CA are treated in the
neonatal units of inpatient obstetric clinics, or in various
general and special (surgical, cardiologic, orthopaedic, etc.)
inpatient and outpatient paediatric clinics. Autopsy was
mandatory for all infant deaths and common (about 80%)
in stillborn fetuses during the study period. Pathologists
sent a copy of the autopsy report to the HCAR if defects
were identiﬁed in stillbirths and infant deaths. Since 1984,
fetal defects diagnosed in prenatal diagnostic centres with or
without termination of pregnancy have also been included
into the HCAR. The total (birth + fetal) prevalence of cases
with CA diagnosed from the second trimester of pregnancy
through the age of one year was 35 per 1000 informative
oﬀspring (liveborn infants, stillborn fetuses, and electively
terminated malformed fetuses) in the HCAR, 1980–1996
[11], and about 90% of major CAs were recorded during the
17 years of the study period [12].
The major objective of the HCCSCA is a postmarket-
ing surveillance of drug teratogenicity [10]; therefore (i)
cases reported after three months of birth or pregnancy
termination were excluded. The longer time between birth
or pregnancy termination and data collection decreases the
accuracy of information about pregnancy history. However,
77%ofcaseswerereportedduringtheﬁrstthree-monthtime
window. (ii) Three mild CAs (such as congenital dysplasia
of hip, congenital inguinal hernia, and large hemangioma),
and (iii) CA syndromes caused by major gene mutations or
chromosomal aberrations with preconceptional origin were
also excluded.
The second step was to ascertain appropriate controls
from the National Birth Registry of the Central Statistical
Oﬃce for the HCCSCA. Controls were deﬁned as newborn
infants without CA. In general, two controls were matched
to every case according to sex, birth week in the year when
the case was born, and district of parents’ residence. These
controls were selected on the basis of case list forwarded
by the coworkers of the HCAR to the administrators of the
National Birth Registry in each quarter of the year, and after
the selection of controls they provided them with name and
address for the coworkers of the HCAR.
The third step was to obtain the necessary maternal and
exposure data from three sources as follows.
(1) Prospective Medically Recorded Data. An explanatory
letter was mailed to mothers immediately after the selection
of cases and controls, and mothers were asked to send us
the prenatal maternity logbook and other medical records
particularly discharge summaries concerning their diseases
during the study pregnancy and their child’s CA. These
documents were sent back after three weeks. Prenatal
care was mandatory for pregnant women in Hungary (if
somebody would not visit prenatal care clinic, she did not
receive a maternity grant and leave), thus nearly 100% of
pregnant women visited prenatal care clinics, an average of
7 times in their pregnancies. The ﬁrst visit was between the
6th and 12th gestational weeks. The task of obstetricians is to
record all pregnancy complications, maternal diseases, and
related drug prescriptions in the prenatal maternity logbook.
(2) Retrospective Self-Reported Maternal Information. a
structured questionnaire with a list of medicinal products
(drugs and pregnancy supplements) and diseases plus a
printed informed consent form were also mailed to the
mothers. The questionnaire requested information on preg-
nancy complications and maternal diseases, on medicinal
products taken during pregnancy according to gestational
months, and on family history of CAs. To standardize the
answers, mothers were asked to read the enclosed lists of
medicinal products and diseases as a memory aid before they
ﬁlled in the questionnaire. We also asked mothers to give a
signature for informed consent form which permitted us to
record their names and addresses in the HCCSCA.
The mean + S.D. time elapsed between the birth or
pregnancy termination and the return of the “information
package” (questionnaire, logbook, discharge summary, and
informed consent form) in our prepaid envelope was 3.5 +
1.2 and 5.2 + 2.9 months in the case and control groups,
respectively.
(3) Supplementary Data Collection. Regional nurses were
asked to visit all nonrespondent case mothers. Regional
nurses helped mothers to ﬁll in the same questionnaire
used in the HCCSCA; they evaluated the available medical
records; in addition, they obtained data regarding smoking
(cigarette/day)anddrinkinghabitthroughcross-interviewof
mothers and fathers or other close relatives living together,
and the so-called family consensus was recorded; ﬁnally,
asked mothers to sign informed consent form. Regional
nurses did not visit all nonrespondent control mothers
because committee on ethics considered this followup to be
disturbing to the parents of healthy children. Thus, only 200
nonrespondentand600respondentcontrolmothersselected
randomly were visited and evaluated in two validation stud-
ies [13, 14]. The diﬀerence of home visit in nonrespondent
families between the groups of cases and controls explains
mainly that the number of controls per cases is 1:1.7 instead
of 1:2.0.
The ﬂow of cases from the HCAR and controls from
the Central Statistical Oﬃce to the HCCSCA and the
achievement of ﬁnal data set were published previously [15].
Overall, the necessary information was available on 96.3%
of cases (84.4% from reply to the mailing, 11.9% from the
nurse visit) and 83.0% of the controls (81.3% from reply,
1.7% from visit). Informed consent form was signed by 98%
of mothers; names and addresses were deleted in the rest of
subjects.
The fourth step of the study was the detailed evaluation
of exposure studies, that is, phenobarbital intake from 11
approaches.ISRN Obstetrics and Gynecology 3
(1) The source of information: phenobarbital treatments
(a)onlyfromtheprenatalmaternitylogbooksand/or
other medical records; (b) only from the question-
naire, and (c) concordant data from both medical
records and the questionnaire.
(2) The type of treatment: two groups were diﬀerenti-
ated: (a) phenobarbital alone and (b) phenobarbital
plus other drugs.
(3) The route of administration: in Hungary, phenobar-
bital was available in the tablet: Sevenal (Alkaloida)
containing 100mg for oral treatment and as ampoule
Sevenal (Chinoin), but parenteral treatment did not
occur in the data set of the HCCSCA.
(4) The dose of phenobarbital treatment: the recom-
mended oral treatment is 1-2 tablets, that is, 100–
200mg per day.
(5) The duration of treatment.
(6) Maternal diseases, that is underlying medical condi-
tions as confounders.
(7) Pregnancy complications.
(8) Other drug uses as confounders.
(9) Pregnancy supplements. The use of pregnancy sup-
plements may indicate the level of pregnancy care,
and indirectly may show the socioeconomic status
and the motivation of mothers to prepare and/or to
achieve a healthy baby. In addition, it is necessary to
consider folic acid and folic acid-containing multivi-
tamins in the evaluation of preventable CAs [16–20].
(10) Thegestationalagewascalculatedfromtheﬁrstdayof
the last menstrual period. Three time intervals were
considered: (i) ﬁrst month of gestation because it
is before the organogenesis, the ﬁrst two weeks are
before conception, while the third and fourth weeks
comprise the pre- and implantation period of zygotes
and blastocysts including omnipotent stem cells, and
it explains the “all-or-nothing eﬀect” rule, that is,
total loss or normal further development. Thus, CAs
cannot be induced by environmental agents in the
ﬁrst month of gestation; (ii) the second and third
monthsofgestation.Thisisthemostsensitive,theso-
called critical period for major CAs; (iii) the fourth
throughninthmonthsofgestation,thatis,pregnancy
after the organ-forming period.
(11) Other confounding factors, such as maternal age,
birth order, marital and employment status as indi-
cator of socioeconomic status [21].
The ﬁfth step of the protocol of the HCCSCA is the
statistical analyses of data.
Statistical analyses were performed using the software
package SAS version 8.02 (SAS Institute Inc., Cary, NC,
USA). First, the occurrence of phenobarbital treatment
during the study pregnancy was compared between the two
study groups (cases and controls), and crude odds ratios
(OR) with 95% conﬁdence interval (CI) were calculated.
Second, frequency tables were made for the main maternal
variables in order to describe the study groups of mothers
with phenobarbital treatment, and of mothers without
phenobarbital treatment as reference. Third, the prevalence
of pregnancy complications, acute and chronic maternal
diseases, other drug treatments and pregnancy supplements
used during the study pregnancy were compared between
case and control mothers with phenobarbital treatment,
and crude OR with 95% of CI was evaluated. Fourth,
the prevalence of phenobarbital treatment was evaluated
according to gestational period in 16 diﬀerent CA groups
including atleast2 casesborn to motherswithphenobarbital
treatmentduringthesecondand/orthirdgestationalmonths
wascomparedwiththefrequencyofphenobarbitaltreatment
in their all matched control pairs, and adjusted OR with
95% CI were evaluated in a conditional logistic regression
model. The latter OR were adjusted for maternal age (<25yr
versus 25–29yr versus 30yr or more), birth order (ﬁrst
delivery versus one or more previous deliveries), maternal
employment status (professional managerial-skilled worker
versus semiskilled worker, unskilled worker, housewife and
others), and fever-related acute maternal diseases (as a
dichotomous variable). The bias connected with multiple
testing was limited by the use of Bonferroni method [22].
3. Results and Discussion
The case group consisted of 22,843 malformed newborns
or fetuses (“informative oﬀspring”) with CAs, of whom 149
(0.65%)hadmotherswithoralphenobarbitaltreatment.The
total number of births in Hungary was 2,146,574 during
the study period between 1980 and 1996. Thus, the 38,151
controls without CA represented (1.8%) of all Hungarian
births, and among those controls, 209 (0.55%) were born to
mothers treated with phenobarbital tablets (crude OR with
95% CI: 1.2, 0.9–1.5).
The analysis of annual data showed a drastic decrease in
the use of phenobarbital during the study period.
Of 149 case mothers, 60 (40.3%), while of 209 control
mothers, 88 (42.1%) had medically recorded oral phenobar-
bital treatments in the prenatal maternity logbooks and/or
discharge summaries (χ2
1 = 0.3; P = 0.59). Most pregnant
women took one tablet (i.e., 100mg) per day. Three or more
tablets were used very rarely. The duration of treatment
was long; the mean was 2.5 and 2.4 months in the case
and control mothers, respectively, because phenobarbital
was used mainly as a sedative drug in Hungary. Only one
case and two control pregnant women were treated with
phenobarbital alone, thus phenobarbital alone and plus
other drugs were combined in our analysis.
Most phenobarbital treatments were recorded in the
3rd gestational month both in the group of cases (no. 38;
25.7%) and controls (no. 54; 25.8%) followed by the 2nd
gestational month (no. 25; 16.9% versus no. 38; 18.2%). The
distribution of gestational months according to the onset of
phenobarbital treatment did not show signiﬁcant diﬀerence
between case and control mothers (χ2
8 = 6.7; P = 0.56).
Table 1 shows the characteristics of mothers with phe-
nobarbital treatment and without phenobarbital treatment4 ISRN Obstetrics and Gynecology
Table 1: Characteristics of mothers.
Maternal variables
Case mothers Control mothers
without with without with
phenobarbital treatment phenobarbital treatment
(N = 22,694) (N = 149) (N = 37,942) (N = 209)
no. % no. % no. % no. %
Quantitative
Maternal age (yr)
24 or less 10,876 47.9 69 46.3 17,882 47.1 112 53.6
25–29 7,106 31.3 48 32.2 12,823 33.8 62 29.7
30 or more 4,712 20.8 32 21.5 7,237 19.1 35 16.7
Mean ± S.D. 25.5 ±5.32 5 .7 ±5.52 5 .5 ±4.92 5 .0 ±4.8
Birth order
1 10,636 46.9 72 48.3 18,095 47.7 114 54.6
2 or more 12,058 53.1 77 51.7 19,847 52.3 95 45.4
Mean ± S.D. 1.9 ±1.11 .7 ±0.91 .7 ±0.91 .6 ±0.9
Categorical
Unmarried 1,264 5.6 5 3.4 1,462 3.9 9 4.3
Employment status
Professional 1,882 8.3 19 12.7 4,335 11.4 18 8.6
Managerial 4,931 21.7 37 24.8 10,076 26.6 58 27.7
Skilled worker 6,291 27.7 38 25.5 11,624 30.6 66 31.6
Semiskilled worker 3,835 16.9 34 22.8 5,744 15.1 39 18.7
Unskilled worker 1,492 6.6 11 7.4 1,843 4.9 16 7.7
Housewife 2,122 9.4 6 4.0 2,034 5.4 4 1.9
Others 2,141 9.4 4 2.7 2,286 6.0 8 3.8
as reference. The mean maternal age and the distribution
of age groups did not show signiﬁcant diﬀerence among
the study groups. The mean birth order was somewhat
lower in mothers with phenobarbital treatment due to
larger proportion of primiparous. There was no signiﬁcant
diﬀerence in the proportion of marital status of mothers
among the study groups. Maternal employment status
showed also some diﬀerences because treated case mothers
were more frequent among professional, managerial, and
semiskilled workers than in untreated case mothers. These
diﬀerences were not seen in control mothers. Thus, there
was some but not signiﬁcant diﬀerence in the distribution
of employment status between case and control mothers
with phenobarbital treatment (χ2
6 :5.3; P = 0.51). The
proportion of smokers was not higher in phenobarbital
treated case mothers (20.8% versus 21.6%) than in untreated
case mothers. The proportion of regular and hard drinkers
did not show signiﬁcant diﬀerence among the study groups.
Among pregnancy complications, the prevalence of
threatened abortions (no. 117; 32.7% versus no. 9,896;
16.3%) and threatened preterm deliveries (no. 79; 22.1%
versus no. 8,015; 13.2%) was more frequent in treated
case and control mothers together because previously some
medical doctors treated these pregnancy complications with
phenobarbital during pregnancy in Hungary. There was no
signiﬁcant diﬀerence in the occurrence of other pregnancy
complications between treated case and control mothers.
The incidence of acute maternal disease did not show
diﬀerence between mothers with or without phenobarbital
treatment either in the case or in the control group with
one exception. Inﬂuenza and common cold (the latter in
generalwithsecondarycomplications)occurredin47treated
case mothers (31.5%) and in 39 treated control mothers
(18.7%) (OR with 95% CI: 2.0, 1.2–3.3). Among chronic
maternal disorders, 95 (0.42%) case mothers and 90 (0.24%)
controlmothershadepilepsy,butonly4casemothers(4.2%)
and 3 control mothers (3.3%) were treated by phenobarbital
(OR with 95% CI: 1.3, 0.4–8.6). Long-term phenobarbital
treatment is recommended for epileptic women based on the
individually deﬁned doses.
The evaluation of other drugs showed that drugs used
for the treatment of threatened abortion (allylestrenol
and promethazine) and preterm delivery (terbutaline and
aminophylline)wereusedmorefrequentlybyphenobarbital-
treated pregnant women. However, their rate did not show
signiﬁcant diﬀerence between case mothers and control
mothers.
Among pregnancy supplements, the use of folic acid was
lower in control mothers (no. 95; 45.5% versus no. 20,680;
54.5%) and particularly in case mothers (no. 59; 39.6%ISRN Obstetrics and Gynecology 5
Table 2: Results of multivariate matched analysis for each case with diﬀerent CAs and its all (1–3) matched controls using conditional
logistic regression model to estimate the adjusted odds ratio (OR) with 95% conﬁdence interval (CI) of oral phenobarbital treatment during
the entire pregnancy and the second and/or third gestational months.
Study groups Grand total Second and third months Entire pregnancy
no. no. % Adjusted OR∗ 95% CI no. % Adjusted OR∗ 95% CI
Isolated CAs
Neural-tube defects 1,202 4 0.3 3.9 0.6–23.4 11 0.9 2.3 0.8–6.1
Cleft lip ± palate 1,374 6 0.4 2.3 0.7–7.9 12 0.9 1.8 0.8–4.3
Posterior cleft palate 582 2 0.3 — — 3 0.5 1.2 0.3–5.5
Intestinal atresia/stenosis 153 1 0.7 — — 2 1.3 3.9 0.3–46.1
Obstructive urinary CAs 271 0 0.0 — — 2 0.7 — —
Hypospadias 3,038 13 0.4 2.3 0.9–5.4 31 1.0 2.6 1.4–4.8
Undescended testis 2,051 6 0.3 1.0 0.3–2.7 16 0.8 1.7 0.8–3.4
Congenital hydrocephaly 314 1 0.3 1.4 0.1–24.9 2 0.6 0.8 0.1–5.2
Ear CAs 354 0 0.0 — — 3 0.9 4.5 0.4–46.2
Cardiovascular CAs 4,479 4 0.1 0.3 0.1–0.9 16 0.4 0.7 0.4–1.3
Clubfoot 2,424 4 0.2 1.9 0.5–7.9 10 0.4 1.0 0.4–2.3
Limb deﬁciencies 548 3 0.6 0.8 0.2–3.3 4 0.7 0.9 0.2–3.3
Poly/syndactyly 1,744 8 0.5 2.6 0.9–7.6 12 0.7 1.5 0.7–3.4
Diaphragmatic CAs 243 0 0.0 — — 4 1.7 2.3 0.5–9.6
Other isolated CAs 2,717 6 0.2 0.9 0.3–2.4 9 0.3 0.5 0.2–1.1
Multiple CAs 1,349 5 0.4 2.5 0.6–9.8 12 0.9 1.6 0.7–3.5
Total case group 22,843 63 0.3 1.3 0.9–1.9 149 0.7 1.3 1.1–1.7
Total control group 38,151 92 0.2 Reference 209 0.6 Reference
∗Matched OR adjusted for maternal age, birth order, maternal employment status, and high fever-related maternal diseases.
Bold numbers show signiﬁcant associations.
versus no. 11,220; 49.4%) with phenobarbital treatment
than in case and control mothers without this treatment.
However, there was no diﬀerence in the occurrence of
folic acid supplementation between treated case and control
mothers (OR with 95% CI: 0.8, 0.5–1.2). At the comparison
of other pregnancy supplements, there was no diﬀerence
among the study groups.
The objective of the study was to evaluate cases with
diﬀerent CAs and their all matched controls (Table 2).
There was a somewhat higher rate of total CAs in mothers
with phenobarbital treatment during the entire pregnancy
compared to control mothers with this treatment (adjusted
OR with 95% CI: 1.3, 1.1–1.7). However, of 16 CA groups
evaluated, only hypospadias based on 31 cases showed a
higher rate of phenobarbital treatment in their mothers.
In the next step, phenobarbital treatment was evaluated
only in the 2nd and/or 3rd gestational months, that is, the
critical period of most major CAs. There was no higher
risk either for the total group of CAs or for any CA group
in cases born to mothers with phenobarbital treatment
during this time window of the study pregnancy. However,
the critical period of hypospadias is in the 3rd and/or
4th gestational months; thus, phenobarbital treatment was
evaluated in this CA during this time window. This approach
showed a signiﬁcant association between hypospadias and
phenobarbital treatment (OR with 95% CI: 2.4, 1.1–5.4).
We evaluated only medically recorded phenobarbital
treatment during the third and fourth gestational months
in the mothers of cases with hypospadias, and a border-
line association was found between phenobarbital use and
hypospadias (adjusted OR with 95% CI: 2.4, 1.0–5.4).
Finally, the Bonferroni adjustment showed that associa-
tion of phenobarbital treatment in the third and/or fourth
gestational months with the risk of hypospadias disappeared
(P = 0.09).
Of 4 cases born to epileptic mothers with phenobarbital
treatment, one had undescended testis (after monotherapy),
one cleft palate (after polytherapy of phenobarbital, carba-
mazepine, and primidone), ventricular septal defect (after
polytherapy of phenobarbital, carbamazepine, and sulthi-
ame), and multiple CA: cleft palate, microtia, ventricular
septal defect, pseudohermaphroditism (after polytherapy
of phenobarbital, primidone, and phenacemide). Thus,
hypospadias did not occur among these cases.
4. Discussion
The objective of our study was to evaluate the possible
association between oral phenobarbital treatment and the
risk for diﬀerent CAs. Our data showed only an association
between hypospadias and phenobarbital treatment during
the critical period of this CA group, but ﬁnally this associ-
ation was not conﬁrmed at the evaluation of only medically
recorded exposure, that is, phenobarbital treatment and after
the consideration of multiple testing bias.6 ISRN Obstetrics and Gynecology
The teratogenic eﬀect of anticonvulsant drugs was con-
ﬁrmed by several studies [4, 5]; however, diﬀerent anticon-
vulsant drugs have diﬀerent risks and spectrum of CAs [23].
Nevertheless, it had become an accepted view that epileptic
pregnant women taking phenobarbital had a 2-3 times
greater risk for delivering a child with CA over the general
newborn population [4, 5]. In general more than one anti-
convulsant drugs (the so-called polytherapy) were used in
epileptic women with seizure during pregnancy; thus, it was
necessary to diﬀerentiate the eﬀect of phenobarbital from
the teratogenic eﬀect of other anticonvulsant drugs [24]. A
higher prevalence of hypoplasia of nails and phalanges was
found in the children of epileptic pregnant women with phe-
nobarbital monotherapy [25]. In the MADRE surveillance
project, 65 epileptic pregnant women had phenobarbital
monotherapy and a higher rate of cardiovascular CAs, and
orofacial cleft was detected in their children [26].
However, several studies did not conﬁrm the teratogenic
potential of phenobarbital. Fedrick [27] studied 41 epileptic
women treated with phenobarbital monotherapy during the
ﬁrst trimester of pregnancy and did not detect a higher rate
of CA in their children. Bethenod and Frederich [28] also
evaluatedepilepticpregnantwomen,andamongthechildren
of 6 pregnant women exposed to phenobarbital, only one
child showed dysmorphic face. The frequency of CAs and
minor anomalies was not greater than expected among
the children of 1,415 women treated with phenobarbital
during the ﬁrst four lunar months in the study of Heinonen
et al. [3]. Robert et al. [29] identiﬁed 40 epileptic pregnant
women with phenobarbital treatment alone, and among
their children, one was aﬀected with ventricular septal defect
while another with hypospadias. In a prospective Italian
study, of 83 pregnant women with phenobarbital therapy,
4 delivered children with CAs (Fallot tetralogy in heart,
hydronephrosis, inguinal hernia with umbilical hernia and
congenial dislocation of the hip) [30]. Rosa et al. [31]
evaluated334fetusesthathadbeenexposedtophenobarbital
during the ﬁrst 15 trimester of pregnancy. A total of 20
(6.0%) major CAs were observed (14 expected). Six CA
groups were analyzed separately on the basis of comparison
of observed and expected numbers, and only cardiovascular
CAs showed a higher observed number (8/3).
Thus, the previous data did not result in unequivocal
ﬁndings regarding the teratogenic eﬀect of phenobarbital
monotherapy during pregnancy. However, it is important to
stress that these studies were preformed in epileptic pregnant
women. Milkovich and Van Den Berg [32] studied 325
nonepileptic pregnant women with barbiturate treatments
and did not ﬁnd a higher rate of CAs in their children.
Shapiro et al. [33] evaluated 8,000 nonepileptic pregnant
women who were treated with phenobarbital during preg-
nancy and they did not ﬁnd a higher rate of CAs in the
children of mothers when the drug was taken for indications
other than epilepsy.
Our study showed a possible association between hypo-
spadias and phenobarbital treatment in nonepileptic preg-
nant women. However, hypospadias show a wide spectrum
of CA from coronal (minor anomaly) through glandular
(mild CA) to penile, penoscrotal and scrotal (severe CA)
types [34]. Our eﬀort was to exclude minor anomalies
such as coronal hypospadias from the data set of the
HCCSCA, but we were not able to check all reports of
cases with unspeciﬁed hypospadias. On the other hand, it
is necessary to diﬀerentiate isolated and multiple-syndromic
categories of hypospadias. Only cases with isolated hypospa-
dias were evaluated in our study. The etiology of isolated
hypospadias is explained by the multifactorial origin, that
is, polygenic-environmental interaction [35, 36]. As far as
we know, only the study of Roberts et al. [29]f o u n da
child with hypospadias after phenobarbital treatment in
epileptic pregnant women. Thus, it is worth considering
phenobarbital among the triggering factors of hypospadias-
related polygenic system, but if we considered only medically
recorded phenobarbital treatment and multiple testing bias,
this association would disappear.
Our data support therefore the statement that use of
phenobarbital in nonepileptic patients does not seem to pose
a signiﬁcant risk for CAs [5]. Nevertheless, the controversial
ﬁndings regarding the teratogenic eﬀect of drugs used in the
small clinical doses by pregnant women and modiﬁed by
several confounding factors are typical in medical teratology.
Another model is necessary to achieve an unequivocal con-
clusion. The so-called disaster epidemiological model seems
to be useful to diminish this dilemma [37]. The Hungar-
ian self-poisoning project in pregnant women, 1960–1993,
included 1,044 pregnant women, and 88 surviving pregnant
women used phenobarbital for their suicide attempt [8].
Doses ranged between 400 and 3,000mg of phenobarbital.
Of88exposedchildren,12(13.6%)wereaﬀectedwithCA.Of
their 78 sib controls, 8 (10.3) had CAs (OR with 95% CI: 1.4,
0.3–3.5). Of 88 pregnant women, 34 attempted suicide with
very large doses of phenobarbital between the 3rd and 12th
postconceptional weeks, that is, during the critical period of
most CAs. Three children were aﬀected with diaphragmatic
CA, multiple CA (but there was no hypospadias among
componentCAs)andundescendedtestis.Oftheother9cases
with CA, only one had penile hypospadias with strabismus,
his mother attempted suicide with 1000mg of phenobarbital
and 12,000mg of meprobamate on the 22nd gestational
week of pregnancy. Thus, there was no overlapping between
the critical period of hypospadias and phenobarbital abuse;
therefore, the disaster epidemiological model did not con-
ﬁrm the possible association of phenobarbital and the higher
risk of hypospadias, and in general the teratogenic eﬀect of
phenobarbital.
Thus, it is worth summarizing that the weaknesses of
previous studies resulted in controversial ﬁndings regarding
the teratogenic potential of phenobarbital. First, the under-
lyingmaternaldiseases,suchasepilepsy,werenotconsidered
at the evaluation of phenobarbital. Though the study of
Holmes et al. [38] concluded that the distinctive pattern of
CAs and minor anomalies observed in infants exposed to
anticonvulsants during pregnancy was caused by the drugs,
rather than by epilepsy itself, we have to consider maternal
diseases among confounders.
Second, the exposure, that is, phenobarbital treatment
was based on retrospective maternal information in most
previous studies; therefore, recall bias might modify theirISRN Obstetrics and Gynecology 7
results. The birth of an infant with CA is a serious traumatic
event for most mothers who therefore try to ﬁnd a causal
explanation such as diseases or drug uses during pregnancy
for CA of their babies. This does not occur after the birth
of a healthy newborn infant. Thus, recall bias might inﬂate
an increased risk for CAs. Our previous analysis showed that
a case-control surveillance of this type may cause spurious
association between drugs and CAs with biased OR up to a
factor of 1.9 [39]. Thus, at the planning of study design it
is necessary to limit recall bias by the evaluation of critical
period of CAs because we expect an underreporting of
phenobarbital treatment in both the critical and noncritical
periods of CAs in the control group. In addition we can
exclude recall bias with the use of only prospectively and
medically recorded data as a gold standard.
Third multiple comparisons may produce a noncausal
association because a signiﬁcant diﬀerence is expected in
every 20th estimation as a result of chance.
The strengths of HCCSCA can be explained by the
population-based and large data set of 358 pregnant women
with phenobarbital treatment in ethnically homogeneous
European (Caucasian) Hungarian population. In addition
potential confounding factors were available for analysis and
additionalstrengthsincludethematchingofcasestocontrols
without CAs. The diagnosis of CAs has a good validity
because cases with CA were reported by medical doctors
and these diagnoses were checked by experts in the HCAR
[11] and later modiﬁed, if necessary, due to the results of
recent medical examinations which were available in the
HCCSCA [10]. Finally, possible biases such as recall and
multiple testing biases were considered.
Of course, limitations of the data set need to be men-
tioned as well. (i) The response rate of case and control
mothers was similar, but all nonrespondent case mothers
were visited at home to collect the necessary data, while it
was performed only in 200 nonrespondent control women.
However, there was no diﬀerence in the distribution and
occurrence of drug treatments and diseases between respon-
dent and nonrespondent mothers in our validation study
[13]. (ii) In addition, there was a longer time between the
end of pregnancy and the return of information package
in the control group than in the case group. However,
this time diﬀerence cannot modify the medically recorded
data. (iii) The HCCSCA is not appropriate to evaluate
other pregnancy outcomes such as miscarriages, in addition
the smoking and drinking habits were evaluated only in
the subsamples of mothers visited at home on the basis
of the so-called “family consensus” through personal cross
interview of mothers and other members of family living
together. This approach was necessary because our previous
validation study indicated the unreliability of retrospective
maternal information regarding their lifestyle during the
study pregnancy [40].
In conclusion, our study showed that phenobarbital
treatment did not associate with a higher risk for total
CAs. Among diﬀerent CA groups, there was a higher risk
of cases with hypospadias born to nonepileptic pregnant
women with phenobarbital treatment. However, this ﬁnding
would disappear if we evaluated only medically recorded
phenobarbital treatments and considered the multiple
testing bias. Thus, the FDA classiﬁcation of phenobarbital as
the pregnancy category D is not correct.
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